Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Lineage Cell Therapeutics, Inc. (LCTX)
Company Research
Source: Business Wire
24 Month Visual Acuity Benefits from a Single Administration with OpRegen® Reported at 2024 Retinal Cell & Gene Therapy Innovation SummitSupported OpRegen for Geographic Atrophy in Phase 2a Study in Collaboration with Roche and GenentechInitiated Activities Under Recently Established Services Agreement with Genentech to Support Ongoing Development of OpRegen ProgramOPC1 Clinical Study Start Up Preparations OngoingHosted 2nd Annual Spinal Cord Injury Investor Symposium CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its second quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.“The second quarter was highlighted by clinical and preclinical execution alongside expanded awareness and data updates o
Show less
Read more
Impact Snapshot
Event Time:
LCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LCTX alerts
High impacting Lineage Cell Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LCTX
News
- Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology WorkshopBusiness Wire
- Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceBusiness Wire
- Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Spinal Cord Injury Treatment Market Size to Worth USD 11 Bn by 2032 [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 [Yahoo! Finance]Yahoo! Finance